Friday, November 19, 2010
arthritis symptoms
rheumatoid arthritis symptoms
In the study, 611 people with moderate to severe rheumatoid arthritis who had an inadequate response to at least one other drug were randomly assigned to one of two doses of tasocitinib or placebo.
Among the findings:
- A total of 66% of patients who received the higher dose of tasocitinib had at least a 20% improvement in disease activity and symptoms after three months of treatment, compared with 60% of those given the lower dose and 27% of those who received a placebo.
- Scores on a questionnaire that asks about dressing, arising, eating, walking, hygiene, reach, grip, and activities improved more than twice as much in people taking either dose of tasocitinib, compared with placebo.
But for the third primary study goal, remission according to the Disease Activity Score-28 (DAS-28) at three months, tasocitinib did not offer a substantial advantage at either dosage relative to placebo.
DAS-28 scores take into account such measures as the number of joints tender to the touch and the number of swollen joints. Using this measure, 10% of patients on the higher tasocitinib dosage, 6% on the lower dose, and 4% on placebo were in remission at three months. But the difference in remission rates did not reach what doctors call statistical significance, Fleischmann tells WebMD. He says he received consulting fees and research support from Pfizer, which makes the drug and funded the new study.
Saturday, August 14, 2010
Boxed Warning Added to Rheumatoid Arthritis Drug Label
The FDA has added information on severe liver injury to the boxed warning for Arava (leflunomide, Sanofiaventis)—a drug used to treat rheumatoid arthritis—to highlight the risk for severe liver injury in patients using this drug and how this risk might be reduced. The FDA previously required a boxed warning stating that leflunomide was contraindicated in pregnant women or women of childbearing potential who were not using reliable contraception.
Although a bolded warning statement on severe liver injury was added to the leflunomide drug label in 2003, the FDA determined that information on severe liver injury should be included in the boxed warning to highlight the importance of appropriate patient selection before starting treatment, and monitoring once treatment has begun.
The decision to add information on severe liver injury to the boxed warning was based on the FDA’s 2010 review of adverse event reports that identified 49 cases of severe liver injury, including 14 cases of fatal liver failure, between August 2002 and May 2009. In this review, the greatest risk for liver injury was seen in patients taking other drugs known to cause liver injury and patients with pre-existing liver disease.
Sunday, July 25, 2010
patients with rheumatoid arthritis is not satisfied with current equipment
Between 80-90 percent of the participants reported at least one negative aspect of self-administration, the study RAISE, which was developed to gain a better understanding of the concerns of these patients using these devices.
Although more than half of patients consider the devices easy to use self-injection, over a third admitted to not knowing if the treatment is administered correctly
The study said 36 percent of patients questioned indicated pain and redness at the injection site, 10 percent admit I miss a dose because of the pain. In addition, 10 percent of patients fail treatment have thought the same reason.
Saturday, January 16, 2010
symptoms of arthritis?
Many of the forms of arthritis, but because they are rheumatic diseases, can cause symptoms affecting various organs of the body that do not directly involve the joints. Therefore, symptoms in some patients with certain forms of arthritis can also include fever, gland swelling (lymph node), weight loss, fatigue, feeling unwell, and even symptoms from abnormalities of organs such as the lungs, heart, or kidneys.